rise rejuvenation semaglutide New Weight Loss Medication Ozempic Face”: An Emerging Drug-Related

doi:10.1016/S0378-5173(00)00423-3 Garidel P, Pevestorf A, Bahrenburg S

The 57.3% reduction in high-sensitivity C-reactive protein observed with oral semaglutide 50 mg would move patients from high cardiovascular risk (greater than 3 mg/dL) to intermediate risk (1-3 mg/dL), independent of glycemic changes

Through the FGF21SIRT1 axis, FGF21 may shift from a protective to a dysregulatory role, exacerbating hepatic lipid accumulation and metabolic imbalance in advanced disease stages

Health Conseq

Tirzepatide Both medications cause gastrointestinal effects during dose escalation, including nausea, vomiting, and constipation